Sign in
Not yet taking people in SpainPhase 1

Tests TT125-802 with other cancer drugs in advanced lung cancer

Tests TT125-802 combined with other drugs in adults with advanced non-small cell lung cancer.

Key facts

Who runs it
TOLREMO therapeutics AG
Where
Barcelona, Madrid, and Pozuelo de Alarcón, SpainSee the 3 sites
Registry title
An Open-label, Multicenter, Phase 1a/1b Study to Evaluate the Safety and Anti-tumor Activity of TT125-802 in Combination With Adagrasib, Osimertinib or Docetaxel in Patients with Advanced NSCLC
Status
Not yet recruiting
Phase
Phase 1
People taking part
40 people, planned
Started
1 Mar 2026
Expected to end
31 Dec 2028
Type of study
Interventional
Record updated
1 June 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with advanced non-small cell lung cancer (NSCLC). It tests TT125-802 together with adagrasib, osimertinib or docetaxel.

Age
18 years or older
Sex
All sexes can join.
Disease stage
Advanced NSCLC

Main reasons for not taking part

  • Healthy volunteers cannot join.

Where in Spain

  • Hospital Quirónsalud BarcelonaBarcelona, SpainNot yet recruiting
  • Hospital Universitario 12 de OctubreMadrid, SpainNot yet recruiting
  • Hospital Universitario Quironsalud MadridPozuelo de Alarcón, SpainNot yet recruiting

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Plain-language title
Tests TT125-802 with other cancer drugs in advanced lung cancerGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
1 June 2026